Press Release: Basilea reports strong 2024 -2-

Basilea Pharmaceutica

40.18 CHF 0.32%

• Charts
• News
• Analysen

Kaufen Verkaufen

Basilea provides the following guidance for the FY 2025:

-- Total revenue is expected to increase by 5.5% to CHF 220 million driven

by an increase in BARDA and CARB-X reimbursements.

-- The expected 14% increase in royalty income to CHF 110 million

reflects primarily the continued strong double-digit sales growth

of Cresemba in its key markets, and fully offsets the impact of

the previously announced decrease in product supply to Pfizer.

-- Following a year of exceptionally high milestone payments in 2024,

milestone and upfront payments in 2025 are expected to be in the

average range of the last few years of around CHF 35 million.

-- The increase in cost and operating expenses reflects our continued

investment in progressing our exciting R&D portfolio of first-in-class

antifungals and antibacterials and is largely offset by the increase in

BARDA and CARB-X reimbursements. As a result, we expect to maintain the

high operating profit level of 2024.

-- We expect no material cash outflow related to income taxes thanks to the

use of tax loss carry forwards, but a 12% income tax rate will be

reflected in the 2025 net profit, in contrast to a CHF 17.3 million

one-time gain from the recognition of deferred tax assets in 2024.

(in CHFm) FY 2025e FY 2024

------------------------------------------- -------- -------

Cresemba and Zevtera-related revenue 190 194.8

------------------------------------------- -------- -------

of which royalty income 110 96.7

------------------------------------------- -------- -------

Total revenue 220 208.5

------------------------------------------- -------- -------

Research & development expenses, net 88 77.1

------------------------------------------- -------- -------

Operating profit 62 61.2

------------------------------------------- -------- -------

Nominations to the board of directors

The board of directors has nominated Leonard Kruimer, Dr. Martin Nicklasson, Dr. Nicole Onetto., Dr. Carole Sable and Dr. Thomas Werner for re-election as board members. After serving on the board of directors for 14 years, Domenico Scala has decided not to stand for re-election. The board has nominated Stephan Schindler for election as a new board member and chairman.

Domenico Scala, chairman, said: "After having served on the board of directors since 2011, and the last nine years as chairman, I decided to not seek re-election at the annual general meeting. In the recent years, Basilea has made significant progress transforming into a focused organization and a leading anti-infectives company. It has an innovative pipeline, robust financials and a highly committed leadership team. The company being in such a strong position, I feel it is the right time to step down as board member and chairman."

The board of directors is proposing the nomination of Stephan Schindler as chairman of the board of directors. He is a highly accomplished executive in the life science industry with over 30 years of experience across finance, operations, corporate governance, and board leadership. From 2009 to 2021 he was Chief Financial Officer of Bachem Holding AG. Prior to this, he was head of Finance of DSM Nutritional Products and previously held various senior finance roles at Roche. He is currently serving on the board of the University Children's Hospital Basel, as chairman of the board of Evolva Holding AG and as board member of Arcondis Holding AG. Mr. Schindler was born and educated in Switzerland and holds Swiss citizenship.

Conference call and webcast

Basilea Pharmaceutica Ltd, Allschwil will host a conference call and webcast today, Tuesday, February 18, 2025, at 4 p.m. (CET), to discuss the company's financial and operating results and to provide an outlook.

Via audio webcast with presentation

The live audio webcast of the results presentation can be followed here: https://event.choruscall.com/mediaframe/webcast.html?webcastid=qyOSTJNH. Please note that there is no function to ask questions via webcast. For questions, please additionally dial-in via phone (see below).

Via phone

To listen by phone and ask questions, please use the dial-in details below. To ensure prompt access, please call approximately 10-15 minutes prior to the scheduled start of the call.

+41 (0) 58 310 5000 (Switzerland, Europe and RoW)

+1 (1) 866 291 4166 (USA)

+44 (0) 207 107 0613 (UK)

Replay

The webcast, along with the presentation will be available https://www.globenewswire.com/Tracker?data=8ASVFx5WFcUO26WTfB8ZN8vxezfmGHseGeI8di1HhT_yNtPS-67i3g0mlOHTHVchPKkVnSOLI-8OCCQBgpDt79d0i6n5gcpAG8ZqksJvpEfwfN0HsCeLIzUVTQuCf9MxROLN0rbhZJTXd5JFh1afjw== online (same link as live audio webcast above) shortly after the event and accessible for three months.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations

Basilea Pharmaceutica International Ltd, Allschwil

Hegenheimermattweg 167b

4123 Allschwil

Switzerland

Phone +41 61 606 1102

E-mail media_relations@basilea.com

investor_relations@basilea.com

This ad hoc announcement can be downloaded from www.basilea.com.

References

1. Biomedical Advanced Research and Development Authority (BARDA) OTA number

75A50124C00033. BARDA is part of the Administration for Strategic

Preparedness and Response (ASPR) within the United States' Department of

Health and Human Services

Attachment

-- Press release (PDF)

https://ml-eu.globenewswire.com/Resource/Download/b03509bc-c5e7-4ce3-9894-1a6350b9d766

(END) Dow Jones Newswires

February 18, 2025 01:15 ET (06:15 GMT)